CIRT	carbon ion radiotherapy
PSA	prostate-specific antigen
ADT	androgen deprivation therapy
LH-RH	luteinizing hormone-releasing hormone
CT	computed tomography
MRI	magnetic resonance imaging
CTV	clinical target volume
PTV	planning target volume
HR-PCa	high-risk prostate cancer
NR	non-recurrence
PR	pseudorecurrence
R	recurrence
AUC	area under the curve
ROC	receiver operating characteristic